The Group's net sales for the third quarter of 2024 amounted to SEK 5.6 million (9.3), down 40 percent year-on-year.

- During the quarter, we continued to deliver in our existing partnerships, with a strong focus on our ability to provide highly specialized services that support our customers in developing high-efficiency flow plates that are adapted to our cost-effective production process, said Daniel Vallin, CEO of Cell Impact.

Financing deemed sufficient for 2025

The cost-saving programs that were implemented in 2023 have now taken full effect. The cash position declined only about SEK 4 million in the quarter, which is a considerably lower rate of decrease and thus a major improvement compared to previous quarters.

- Given the capital contribution that the company received in the recently completed share issue, our current assessment is that the company is sufficiently financed for 2025. This provides us with good prospects to continue developing our operations and our production facility, making us more attractive as a partner and supplier, said Daniel Vallin.

• Net sales totaled SEK 5.6 million (9.3).
• Operating loss (EBIT) was SEK -17.7 million (-23.7).
• The Group's result after financial items was SEK -17.7 million (-24.9).
• Earnings per share attributable to the Parent Company's shareholders before and after dilution totaled SEK -0.03 (-0.33).
• Debt/equity ratio was 84 percent (75) on the balance sheet date.
• Cash flows from operating activities amounted to SEK 0.8 million (-26.3).
• On the balance sheet date, the Group's cash and cash equivalents totaled SEK 18.2 million (35.1).
• On November 5, the company's cash and cash equivalents amounted to SEK 30.9 million.

This information is inside information that Cell Impact AB is obliged to make public pursuant to the EU Market Abuse Regulation.